Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
According to Nautilus Biotechnology, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
Year | P/S ratio |
---|---|
2023 | 0.00 |
2022 | 0.00 |
2021 | 0.00 |
2020 | 0.00 |
2019 | 0.00 |
2018 | 0.00 |